Based on the fact that PTPRO can sensitize cancer cells to different therapies (Ramaswamy et al., 2009; Asbagh et al., 2014), we overexpressed PTPRO in ERBB2-positive cancer cells and demonstrated that the overexpressed PTPRO is capable of reversing lapatinib-insensitivity. Here, ERBB2 is linked to cancer.